Navigation Links
LX211 highlighted as potential disease modifying therapy for noninfectious uveitis
Date:10/29/2009

JERSEY CITY, NJ (October 26, 2009): An experimental drug, LX211 (LUVENIQ; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27, highlight the ability of LX211 to control the inflammation that characterizes this potentially blinding eye disease and significantly reduce its rate of recurrence. Lux Biosciences plans to file an NDA and MAA for marketing approvals around year-end 2009 and early 2010 in the United States and Europe, respectively.

"The LX211-02 study was a double-masked, placebo-controlled, dose-ranging study that included 232 patients at 57 centers in North America, Europe and India with clinically inactive uveitis involving any location within the eye," said Bahram Bodaghi, M.D., Ph.D., Piti Salptrire Hospital Paris, France, who will present the study results on Monday October 26 at 8:50 am PT. "Results of this trial showed that LX211 was able to reduce recurrence of inflammation by 50% over placebo at the 0.4 mg/kg twice daily dose (p<0.05) and may therefore effectively increase the interval between inflammatory relapses to 24 months compared to 10 months with placebo."

"Given that inflammatory exacerbation is a direct trigger of vision loss," Prof. Bodaghi commented, "this result for LX211 is impressive. In addition to a marked reduction in recurrence of inflammation, visual acuity was preserved in this study. Moreover, these results suggest the potential for disease modification whereby treatment with LX211 alters the course of the disease leading u
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels
2. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
3. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
4. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
5. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
6. Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending PCT Shredder at the Meeting
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
10. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
11. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
(Date:5/20/2015)... May 20, 2015  Cypher Genomics, Inc., a ... with Celgene Corporation to apply Cypher,s Coral TM ... associate with patient response to innovative medicines. The ... help accelerate patient access to the right medicine ... research and development and potentially inform new companion ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdsx2f/bone ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 and ... - Maxillofacial) - Global Industry Analysis, Size, Share, ... report to their offering. The global ... the types of recombinant BMPs, applications, and geography. ...
Breaking Biology Technology:Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... , EL SEGUNDO, Calif., July 27 ... contract with Wyle to provide continuing support to the Space Life ... contract to April 30, 2013. The work will be done ... , Under the bioastronautics contract, Wyle,s work supports ...
... , SOUTH PLAINFIELD, N.J., July 27 ... a Phase 2 clinical trial of PTC299 in adult patients ... causes the development of non-malignant brain tumors. PTC299 is ... to selectively block tumor-related vascular endothelial growth factor (VEGF). ...
... KEELE, England, July 27 A recent independent ... Orthobiologics,Company, Biocomposites, ( http://www.biocomposites.com ), as an ... due,to its unique negative zeta potential control (ZPC(TM)). ... out by the hospital and departments of the,university ...
Cached Biology Technology:NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts 2
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... In a head-to-head battle of harvesting the sun,s energy, solar ... Science . But scientists think they can even up the ... Plants are less efficient at capturing the energy in ... evolutionary baggage. Plants have to power a living thing, whereas ...
... A new study involving Canada,s Centre for Addiction and ... type of intellectual disability called Joubert syndrome. CAMH ... when defective, leads to Joubert syndrome. This research is published ... This international study combined Dr. Vincent,s gene mapping of ...
... the RIKEN Plant Science Center (PSC) have clarified a ... model plant Arabidopsis protects cells from harmful DNA elements. ... PLoS Genetics , the finding contributes to advancing ... in both plants and animals, opening the door to ...
Cached Biology News:Solar cells more efficient than photosynthesis -- for now 2CAMH researcher discovers new gene that causes intellectual disability 2Discovery of DNA silencing mechanism reveals how plants protect their genome 2
Caveolin Sampler Kit 10g each...
Slide Chambers are convenient for performing pre-hybridization incubations and post-hybridization washes with tissue sections mounted on standard glass microscope slides. Each chamber holds up to 5 s...
Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: